Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

about

Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

Item

http://www.wikidata.org/entity/Q48096316

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

@en

Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

@nl

type

Item

label

Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

@en

Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

@nl

prefLabel

Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

@en

Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

@nl

P1476

Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

@en

P2093

Andrei Iagaru

http://www.w3.org/2001/XMLSchema#string

Lucia Baratto

http://www.w3.org/2001/XMLSchema#string

P2860

International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

Cancer statistics, 2016

Regulation and signaling of human bombesin receptors and their biological effects.

F-Labeled GRPR Agonists and Antagonists: A Comparative Study in Prostate Cancer Imaging.

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

Targeting prostate cancer with radiolabelled bombesins.

Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update.

Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes.

PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues.

P2888

s11307-017-1151-1

P304

501-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S11307-017-1151-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hossein Jadvar

P577

2017-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29256046

http://www.w3.org/2001/XMLSchema#string